Label-Free Multiphoton Microscopy for intraoperative Identification of Glioma Features and Tumor Heterogeneity - Top-Institutions - MDSpire

Label-Free Multiphoton Microscopy for intraoperative Identification of Glioma Features and Tumor Heterogeneity

  • By

  • Duncker, León V.

  • Richter, Sven

  • Galli, Roberta

  • Meinhardt, Matthias

  • Hoffmann, Leon C.

  • Kirsche, Katrin

  • Großer, Lidia

  • Temme, Achim

  • Eyüpoglu, Ilker Y.

  • Uckermann, Ortrud

  • June 22, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    NYU Langone Health (NYU Grossman School of Medicine)
    NYU Langone Health (NYU Grossman School of Medicine)

    New York, New York

    Key Differentiators

    • Neurosurgery

  • #2

    University Hospital Münster
    University Hospital Münster

    Münster, North Rhine-Westphalia

    Key Differentiators

    • Neurosurgery

  • #3

    Charing Cross Hospital, Imperial College Healthcare NHS Trust
    Charing Cross Hospital, Imperial College Healthcare NHS Trust

    London, England

    Key Differentiators

    • Neurosurgery

  • #4

    Leipzig University
    Leipzig University

    Leipzig, Saxony

    Key Differentiators

    • Neurosurgery

  • #5

    Medical University of Vienna
    Medical University of Vienna

    Vienna, Vienna

    Key Differentiators

    • Neurosurgery

Original Source(s)

Label-Free Multiphoton Microscopy for intraoperative Identification of Glioma Features and Tumor Heterogeneity

  • by Duncker, León V., Richter, Sven , Galli, Roberta , Meinhardt, Matthias , Hoffmann, Leon C., Kirsche, Katrin , Großer, Lidia , Temme, Achim , Eyüpoglu, Ilker Y., Uckermann, Ortrud

  • June 22, 2026

Related Content

A pharmacodynamic study of rapid lactate metabolic modulation by intravenous L-arginine in brain metastases

High-grade astrocytoma with piloid features: a case report of comprehensive management

Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial